Condition 1: Heart failure. Condition 2: ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction. Heart failure ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
Intervention 1: Intervention group 1: Patients will receive 25 mg of empagliflozin daily for three months with standard treatments. Intervention 2: Intervention group 2: Patients will receive 1 mg of
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Heart Failure with Reduced Ejection Fraction Aged 18 to 80 years Consented patients
Exclusion criteria
Exclusion criteria: Pregnancy Lactation Liver failure Kidney failure Contraindications of colchicine or empagliflozin Systolic blood pressure less than 100 or more than 180 mm Hg Symptomatic hypotension Autoinflammatory diseases Malignancy Diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-sensitivity C-reactive protein (hs-CRP). Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;New York Heart Association (NYHA) Functional Classification. Timepoint: At baseline and 1, and 3 months after intervention. Method of measurement: Assessment by one cardiologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Echocardiography.;Left ventricular end-diastolic diameter. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Echocardiography.;Mitral valve regurgitation grade. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Echocardiography.;Tumour Necrosis Factor alpha (TNF alpha). Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;Ejection fraction. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Echocardiography.;Total antioxidant capacity. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;Malondialdehyde. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Laboratory test.;?Empagliflozin serum concentration. Timepoint: One and three months after intervention. Method of measurement: Laboratory test.;Left ventricular diastolic function. Timepoint: One and three months after intervention. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTaher Entezari-Maleki
Tabriz University of Medical Sciences
Outcome results
None listed